Kim, Won Young team published research in Nano-Micro Letters in 2021 | 4224-70-8

Reference of 4224-70-8, 6-bromohexanoic acid is an organobromine compound comprising hexanoic acid having a bromo substituent at the 6-position. It derives from a hexanoic acid.
6-Bromohexanoic acid is a useful research compound. Its molecular formula is C6H11BrO2 and its molecular weight is 195.05 g/mol. The purity is usually 95%.
6-Bromohexanoic acid is useful for the preparation of anti-CTLA4 compounds as antitumor agents.
6-Bromohexanoic acid is a fatty acid that has been shown to be an effective agent for the treatment of cancer. It is used in gene therapy to inhibit the growth of cancer cells by binding to and then activating transcription factors. 6-Bromohexanoic acid can also be used as a chemotherapeutic agent and has been shown to cause apoptosis in monoclonal antibody-treated cells. 6-Bromohexanoic acid has pharmacokinetic properties that are similar to those of other fatty acids. The reaction solution was found to have high chemical stability, which may be due to the presence of nitrogen atoms. This reaction solution was found to adsorb onto the surface of monoclonal antibodies and cell culture, altering their properties., 4224-70-8.

Dehydrobromination, Grignard reactions, reductive coupling, Wittig reaction, and several nucleophilic substitution reactions are some of the principal reactions which involve organic bromides. 4224-70-8, formula is C6H11BrO2, Name is 6-Bromohexanoic acid. Organic compounds having carbon bonded to bromine are called organic bromides. Reference of 4224-70-8.

Kim, Won Young;Won, Miae;Koo, Seyoung;Zhang, Xingcai;Kim, Jong Seung research published 《 Mitochondrial H2Sn-mediated anti-inflammatory theranostics》, the research content is summarized as follows. The insistent demand for space-controllable delivery, which reduces the side effects of non-steroidal anti-inflammatory drugs (NSAIDs), has led to the development of a new theranostics-based approach for anti-inflammatory therapy. The current anti-inflammatory treatments can be improved by designing a drug delivery system responsive to the infammatory site biomarker, hydrogen polysulfde (H2Sn). Here, we report a novel theranostic agent 1 (TA1), consisting of three parts: H2Sn-mediated triggering part, a two-photon fuorophore bearing mitochondria targeting unit (Rhodol-TPP), and anti-infammatory COX inhibitor (indomethacin). In vitro experiments showed that TA1 selectively reacts with H2Sn to concomitantly release both Rhodol-TPP and indomethacin. Confocal-microscopy imaging of infammation-induced live cells suggested that TA1 is localized in the mitochondria where the H2Sn is overexpressed. The TA1 reacted with H2Sn in the endogenous and exogenous H2Sn environments and in lipopolysaccharide treated infammatory cells. Moreover, TA1 suppressed COX-2 level in the infammatory-induced cells and prostaglandin E2 (PGE2) level in blood serum from infammation-induced mouse models. In vivo experiments with infammation-induced mouse models suggested that TA1 exhibits infammation-site-elective drug release followed by signifcant therapeutic efects, showing its function as a theranostic agent, capable of both anti-infammatory therapy and precise diagnosis. Theranostic behavior of TA1 is highly applicable in vivo model therapeutics for the infammatory disease.

Reference of 4224-70-8, 6-bromohexanoic acid is an organobromine compound comprising hexanoic acid having a bromo substituent at the 6-position. It derives from a hexanoic acid.
6-Bromohexanoic acid is a useful research compound. Its molecular formula is C6H11BrO2 and its molecular weight is 195.05 g/mol. The purity is usually 95%.
6-Bromohexanoic acid is useful for the preparation of anti-CTLA4 compounds as antitumor agents.
6-Bromohexanoic acid is a fatty acid that has been shown to be an effective agent for the treatment of cancer. It is used in gene therapy to inhibit the growth of cancer cells by binding to and then activating transcription factors. 6-Bromohexanoic acid can also be used as a chemotherapeutic agent and has been shown to cause apoptosis in monoclonal antibody-treated cells. 6-Bromohexanoic acid has pharmacokinetic properties that are similar to those of other fatty acids. The reaction solution was found to have high chemical stability, which may be due to the presence of nitrogen atoms. This reaction solution was found to adsorb onto the surface of monoclonal antibodies and cell culture, altering their properties., 4224-70-8.

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary